Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707557 | 1.00 | MAPT (0.32) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL20647297 | 0.94 | PIM3 (0.32) | MAPTSMN1; SMN2PDK2KDM4EMEN1 | |
| SCHEMBL20647391 | 0.94 | PIM3 (0.32) | MAPTSMN1; SMN2PDK2KDM4EMEN1 | |
| SCHEMBL21707556 | 0.92 | MEN1 (0.36) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL21707575 | 0.92 | MEN1 (0.36) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL20647396 | 0.91 | MAPT (0.34) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL20647407 | 0.91 | MAPT (0.34) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL23263493 | 0.87 | MAPT (0.35) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL21707566 | 0.87 | MAPT (0.35) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL21707552 | 0.87 | MAPT (0.35) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718606-B2 | Polycyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-11718606-B2 | Polycyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-20200048232-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048232-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, CYP1A1 | MAPT 1909/4885SMN1; SMN2 4272/4885ALDH1A1 44/4885 |
| US-11718606-B2 | Polycyclic compound and organic light emitting element comprising same | CRY1, CRY2, CYP1A1 | MAPT 1909/4885SMN1; SMN2 4272/4885ALDH1A1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.